Development of a specific activin antagonist for therapeutic applications

开发用于治疗应用的特异性激活素拮抗剂

• 批准号: nhmrc : 1006488
• 负责人: A/Pr Craig Harrison
• 金额: $ 33.63万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-specific-activin-therapeutic-applications/109186
• 关键词: Development; specific; activin; antagonist; therapeutic

Activin is a key regulator of homeostasis in several organs and tissues, including ovaries, testes, liver and skin, and alterations in activin�s activity can result in fibrosis, cachexia and cancer. In this grant we propose to develop a specific activin antagonist by modifying the activin A propeptide. This novel reagent could be used to promote liver growth in severe hepatic disease and prevent fibrosis in numerous tissues.

激活素是几种器官和组织（包括卵巢、睾丸、肝脏和皮肤）内稳态的关键调节因子，激活素活性的改变可导致纤维化、恶病质和癌症。本研究拟通过对激活素A前肽的修饰，开发一种特异性的激活素拮抗剂。这种新型试剂可用于促进严重肝病中的肝脏生长，并防止许多组织中的纤维化。